| Jan 30 2015 |
Inherency Requires Factual Evidence that a Limitation Is Necessarily Present or Is the Natural Result |
McDermott Will & Emery |
| Jan 30 2015 |
Court Greenlights “Usual and Customary” Medicare Fraud Case |
Mahany Law |
| Jan 30 2015 |
Statute Intended to Close Deepsouth Loophole Given Broad Interpretation: Promega Corp. v. Life Techs. Corp. |
McDermott Will & Emery |
| Jan 30 2015 |
Even Further Down the Rabbit Hole: New EU Legislation Adds to GMO Quagmire |
Mintz |
| Jan 29 2015 |
Supreme Court Holds Claim Construction Facts Are Subject to Clear Error Review |
Honigman Miller Schwartz and Cohn LLP |
| Jan 29 2015 |
Federal Circuit to Myriad: Neither DNA Primers nor Comparing Gene Sequences Are Patent-Eligible Subject Matter |
McDermott Will & Emery |
| Jan 29 2015 |
Brazil Mailbox Litigation Update: Good News to Start the Year for the Pharmaceutical Industry |
Michael Best & Friedrich LLP |
| Jan 28 2015 |
Medical Device Update: FDA Releases General Wellness Products and Device Accessories Guidance Documents |
Morgan, Lewis & Bockius LLP |
| Jan 28 2015 |
Pennsylvania Court Strengthens Rejection of “Every Breath” Theory re: Asbestos Exposure |
Steptoe & Johnson PLLC |
| Jan 27 2015 |
Telemedicine has an Unlikely Ally: The Federal Trade Commission (FTC) |
Epstein Becker & Green, P.C. |
| Jan 27 2015 |
Summary Report of European Commission’s mHealth Consultation Published |
Covington & Burling LLP |
| Jan 27 2015 |
Will Promoted Video Pave the Way for Drug and Medical Device Promotion on Twitter? |
Epstein Becker & Green, P.C. |
| Jan 26 2015 |
Par Pharmaceutical, Inc., Roxane Laboratories, Inc., and Amneal Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc.: Denying Institution of Covered Business Method Review |
Faegre Drinker |
| Jan 23 2015 |
FDA Issues Guidance for Low-Risk General Wellness Products |
Sheppard, Mullin, Richter & Hampton LLP |
| Jan 22 2015 |
Patent Claim Construction Now Subject to Hybrid Review: Teva Pharmaceutical v. Sandoz |
McDermott Will & Emery |
| Jan 22 2015 |
Can Digital Healthcare Innovation Be Patented? Eligibility of Digital Healthcare Technologies Under the New USPTO Eligibility Guidelines |
Sterne, Kessler, Goldstein & Fox P.L.L.C. |
| Jan 22 2015 |
Egypt and Blumberg Grain Launch World’s Largest Integrated Food Storage System |
Covington & Burling LLP |
| Jan 22 2015 |
Study Identifies Progress and Challenges in E-Prescribing Controlled Substances |
Covington & Burling LLP |
| Jan 22 2015 |
Goose Cooked? Foie Gras Producers Victorious, Sales and Marketing to Resume in California |
Morgan, Lewis & Bockius LLP |
| Jan 21 2015 |
New French Rules On Off-Label Use |
Covington & Burling LLP |
| Jan 21 2015 |
Teva v. Sandoz pt.II– The Dissent And The Zone Of Uncertainty |
Schwegman, Lundberg & Woessner, P.A. |
| Jan 21 2015 |
Teva Pharmaceuticals v. Sandoz: Supreme Court Changes Standard of Review in Claim Construction Case |
Michael Best & Friedrich LLP |
| Jan 21 2015 |
Claim Construction in Patents: Teva v. Sandoz: “Just the facts, Ma’am” |
Schwegman, Lundberg & Woessner, P.A. |
| Jan 20 2015 |
Giant Multinational Unilever Drops Suit Against Innovative Start-up Hampton Creek Over Eggless “Mayonnaise” |
Covington & Burling LLP |
| Jan 20 2015 |
FDA Issues Draft Guidance on Policy for Low Risk Devices for General Wellness |
Barnes & Thornburg LLP |
| Jan 20 2015 |
Myriad’s Fight Continues: Federal Circuit Finds Composition and Method Claims Ineligible |
Covington & Burling LLP |
| Jan 20 2015 |
Promega v. Life Technologies – “Too Much Of Nothing?” re: Patent Infringement |
Schwegman, Lundberg & Woessner, P.A. |
| Jan 20 2015 |
CFDA Proposes New Regulations on the Accreditation of Medical Device Trial Sites: China Food and Drug Administration |
Covington & Burling LLP |
| Jan 19 2015 |
Washington Federal Judge Allows RCRA Citizen Suit Over Manure Management to Proceed--Resource Conservation and Recovery Act |
Michael Best & Friedrich LLP |
| Jan 16 2015 |
FDA Publishes Draft Guidances Describing General Wellness Claims and Risk-Based Classification of Accessories |
Covington & Burling LLP |
| Jan 16 2015 |
FDA Proposes to Apply Risk-Based Framework to Accessory Devices |
Mintz |
| Jan 16 2015 |
Fifth Circuit Holds That Product Development Protocol Has Same Preemptive Effect As Premarket Approval |
Covington & Burling LLP |
| Jan 15 2015 |
Pharmacy Qui Tam Based On U&C Price Billing Survives Motion to Dismiss |
Mintz |
| Jan 15 2015 |
CMS Releases EHR (Electronic Health Records) Incentive Program Data |
Covington & Burling LLP |
| Jan 14 2015 |
Torrent Pharmaceuticals Limited v. Merck Frosst Canada & Co.: Denying Petitioner’s Request for Rehearing of Decision on Institution IPR2014-00559 |
Faegre Drinker |
